ABBV: Pipeline innovation and strategic deals fuel robust growth in immunology and neuroscience
Strong pipeline momentum is driving growth across immunology, oncology, and neuroscience, with major late-stage assets and innovative combination therapies advancing. Strategic acquisitions like Apogee and new AI initiatives are enhancing long-term prospects, while policy efforts focus on sustainin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.